Propanc Biopharma targets February 2027 first-patient dosing for Phase 1b PRP cancer trial

• Propanc outlined new preclinical pancreatic cancer results for PRP, already presented in a newly released data package.
• Studies showed strong tumor control, fewer metastases, longer survival, and signs of improved response to standard chemotherapy.
• PRP uses a differentiation-based approach rather than RAS inhibition, positioning it as a potential complement to emerging RAS-targeted drugs.
• Next catalyst is a planned Phase 1b first-in-human trial in advanced solid tumors, with first patient dosing targeted for February 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220830PRIMZONEFULLFEED9830289) on September 22, 2026, and is solely responsible for the information contained therein.